In a seminal work, Shikha Nayar et al. found that blocking the common cytokine receptor subunit gp130 ameliorates CD, and proposed gp130 as a therapeutic target for patients who do not respond to anti-TNF therapies and also as a supplemental therapy in addition to the standard treatments for patients with moderate to severe CD (39). This evidence concerns the gene TNF and Cowden disease.